Joseph J. Buggy

17.4k total citations · 5 hit papers
83 papers, 7.2k citations indexed

About

Joseph J. Buggy is a scholar working on Genetics, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Joseph J. Buggy has authored 83 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Genetics, 41 papers in Molecular Biology and 23 papers in Pathology and Forensic Medicine. Recurrent topics in Joseph J. Buggy's work include Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (21 papers) and Histone Deacetylase Inhibitors Research (14 papers). Joseph J. Buggy is often cited by papers focused on Chronic Lymphocytic Leukemia Research (45 papers), Lymphoma Diagnosis and Treatment (21 papers) and Histone Deacetylase Inhibitors Research (14 papers). Joseph J. Buggy collaborates with scholars based in United States, Spain and Netherlands. Joseph J. Buggy's co-authors include Betty Chang, Erik Verner, Mint Sirisawad, Sriram Balasubramanian, Richard A. Miller, Lee Honigberg, Jan A. Burger, Ahmed Hamdy, David Loury and Carl E. Bauer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Joseph J. Buggy

81 papers receiving 7.1k citations

Hit Papers

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-c... 2010 2026 2015 2020 2010 2012 2011 2011 2012 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
    2010 1.2k citations Lee Honigberg, Mint Sirisawad et al. profile →
  2. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
    2012 848 citations Ranjana H. Advani, Joseph J. Buggy et al. Journal of Clinical Oncology profile →
  3. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
    2011 607 citations Sarah E. M. Herman, Amber Gordon et al. Blood profile →
  4. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
    2011 499 citations Joseph J. Buggy et al. Blood profile →
  5. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
    2012 407 citations Martin F. M. de Rooij, Annemieke Kuil et al. Blood profile →

Peers

Joseph J. Buggy
Betty Chang United States
Enrique M. Ocio Spain
Taghi Manshouri United States
Neill A. Giese United States
Marcel Spaargaren Netherlands
Juan C. Cigudosa Spain
Edward A. Fox United States
Suzanne Trudel Canada
Ruth Rimokh France
Jérôme Moreaux France
Betty Chang United States
Joseph J. Buggy
Citations per year, relative to Joseph J. Buggy Joseph J. Buggy (= 1×) peers Betty Chang

Countries citing papers authored by Joseph J. Buggy

Since Specialization
Citations

This map shows the geographic impact of Joseph J. Buggy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph J. Buggy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph J. Buggy more than expected).

Fields of papers citing papers by Joseph J. Buggy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph J. Buggy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph J. Buggy. The network helps show where Joseph J. Buggy may publish in the future.

Co-authorship network of co-authors of Joseph J. Buggy

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph J. Buggy. A scholar is included among the top collaborators of Joseph J. Buggy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph J. Buggy. Joseph J. Buggy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosenbaum, James T., Erik Verner, William B. Jones, et al.. (2024). Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity. 1(1). 3 indexed citations
2.
Willingham, Stephen B., Po Y. Ho, Andrew Hotson, et al.. (2018). A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models. Cancer Immunology Research. 6(10). 1136–1149. 162 indexed citations
3.
Smith, David, Leanne Goldstein, Mei Cheng, et al.. (2014). Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib. Annals of Hematology. 94(2). 249–256. 8 indexed citations
4.
Chang, Betty, Michelle Francesco, Martin F. M. de Rooij, et al.. (2013). Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 122(14). 2412–2424. 159 indexed citations
5.
Herman, Sarah E. M., Ellen X. Sun, Erin M. McAuley, et al.. (2013). Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 27(12). 2311–2321. 64 indexed citations
6.
Shinohara, Masahiro, Betty Chang, Joseph J. Buggy, et al.. (2013). The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. Bone. 60. 8–15. 46 indexed citations
7.
Cheng, Shuhua, Jiao Ma, Ailin Guo, et al.. (2013). BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 28(3). 649–657. 153 indexed citations
8.
Advani, Ranjana H., Joseph J. Buggy, Jeff P. Sharman, et al.. (2012). Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. Journal of Clinical Oncology. 31(1). 88–94. 848 indexed citations breakdown →
9.
Buggy, Joseph J. & Laurence Elias. (2012). Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy. International Reviews of Immunology. 31(2). 119–132. 172 indexed citations
10.
Chang, Betty, Min Huang, Michelle Francesco, et al.. (2011). The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Research & Therapy. 13(4). R115–R115. 174 indexed citations
11.
MacGlashan, Donald W., Lee Honigberg, Ashley Smith, Joseph J. Buggy, & John T. Schroeder. (2011). Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor. International Immunopharmacology. 11(4). 475–479. 50 indexed citations
12.
Herman, Sarah E. M., Amber Gordon, Erin Hertlein, et al.. (2011). Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 117(23). 6287–6296. 607 indexed citations breakdown →
13.
Bhalla, Savita, Sriram Balasubramanian, Kevin A. David, et al.. (2009). PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells. Clinical Cancer Research. 15(10). 3354–3365. 82 indexed citations
14.
Balasubramanian, Sriram, Jason Ramos, Weigang Luo, et al.. (2008). A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 22(5). 1026–1034. 363 indexed citations
15.
Loury, David, et al.. (2007). PCI-27483, a small molecule inhibitor of factor VIIa, inhibits tumor growth in vivo.. Molecular Cancer Therapeutics. 6. 1 indexed citations
16.
Buggy, Joseph J., et al.. (1996). Human Glucagon Receptor Monoclonal Antibodies: Antagonism of Glucagon Action and Use in Receptor Characterization. Hormone and Metabolic Research. 28(5). 215–219. 7 indexed citations
17.
Heurich, Rainer O., Joseph J. Buggy, Mark Vandenberg, & Anthony Rossomando. (1996). Glucagon Induces a Rapid and Sustained Phosphorylation of the Human Glucagon Receptor in Chinese Hamster Ovary Cells. Biochemical and Biophysical Research Communications. 220(3). 905–910. 9 indexed citations
18.
Buggy, Joseph J., James N. Livingston, Daniel U. Rabin, & H Yoo-Warren. (1995). Glucagon·Glucagon-like Peptide I Receptor Chimeras Reveal Domains That Determine Specificity of Glucagon Binding. Journal of Biological Chemistry. 270(13). 7474–7478. 52 indexed citations
19.
Aksamit, Robert R., Joseph J. Buggy, & Carl E. Bauer. (1995). Expression of Rat Liver Adohcy Hydrolase in a Rhodobacter capsulatus ahcY Mutant Restores Pigment Formation and Photosynthetic Growth. Biochemical and Biophysical Research Communications. 207(1). 265–272. 2 indexed citations
20.
Buggy, Joseph J., et al.. (1995). Isolation and Structural-Analysis of the 5′ Flanking Region of the Gene Encoding the Human Glucagon Receptor. Biochemical and Biophysical Research Communications. 208(1). 339–344. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Betty Chang Breakdown of academic impact, for papers by Enrique M. Ocio Breakdown of academic impact, for papers by Taghi Manshouri Breakdown of academic impact, for papers by Neill A. Giese Breakdown of academic impact, for papers by Marcel Spaargaren Breakdown of academic impact, for papers by Juan C. Cigudosa Breakdown of academic impact, for papers by Edward A. Fox Breakdown of academic impact, for papers by Suzanne Trudel Breakdown of academic impact, for papers by Ruth Rimokh Breakdown of academic impact, for papers by Jérôme Moreaux
Rankless by CCL
2026